TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

A Randomized, Placebo-controlled, Double-blind Pilot Study of Single-dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa loa Infection.

Fanny Legrand et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.